mesothelioma treatment 2026

Four FDA-approved first-line regimens, MARS2 reshaped surgery, CheckMate 743 5-year data — the 2025–2026 mesothelioma treatment landscape, explained.

Review 2026 expert consensus on pleural mesothelioma surgery, including P/D vs EPP data, patient selection, and perioperative immunotherapy trials.

TTFields therapy with Optune Lua achieved 18.2-month median survival in the STELLAR trial. Learn how this FDA-approved device works for mesothelioma treatment in 2026.

Real-world data reveals older mesothelioma patients on immunotherapy survive 25% less than clinical trial participants. Learn what the gap means for treatment decisions.

The FDA approved a subcutaneous Opdivo formulation that takes 5 minutes instead of 60. Learn how this new nivolumab injection changes treatment for mesothelioma patients.